Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
1. A nucleotide sequence comprising a coding sequence encoding a monomer that comprises the second VEGF binding domain (D2) of FMS-like tyrosine kinase-1 (FLT-1), wherein said monomer comprises the amino acid sequence of SEQ ID NO:1, or an amino acid sequence with at least 95% sequence identity thereto; wherein the monomer further comprises one or more cysteine residues; wherein the one or more cysteine residues are C-terminal to the amino acid sequence of SEQ ID NO:1; wherein at least two of said monomer can form an oligomer; wherein the oligomer exhibits enhanced stability compared to soluble FLT-1 (sFLT01).
2. The nucleotide sequence of claim 1 , wherein said nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:2.
3. An expression vector comprising the nucleotide sequence of claim 1 , operably linked to expression control elements.
4. A host cell comprising the expression vector of claim 3 .
5. A method for producing one or more monomers that comprise the second VEGF binding domain (D2) of FMS-like tyrosine kinase-1 (FLT-1), said method comprising:
(a) providing host cells according to claim 4 ; and
(b) culturing the host cells under conditions whereby the monomer encoded by the coding sequence present in the expression vector is expressed.
6. The method of claim 5 , wherein the method further comprises (c) recovering one or more monomers from the host cells.
7. A method of producing a VEGF antagonist oligomer wherein said oligomer comprises a plurality of monomers linked to each other, wherein each monomer comprises the second VEGF binding domain (D2) of FMS-like tyrosine kinase-1 (FLT-1), wherein each monomer further comprises one or more cysteine residues, wherein the one or more cysteine residues are C-terminal to the second VEGF binding domain of FLT-1; said method comprising:
(a) providing host cells comprising an expression vector that comprises a coding sequence encoding said monomer, wherein said monomer comprises the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence with at least 95% sequence identity thereto;
(b) culturing the host cells under conditions whereby the monomer encoded by the coding sequence present in the expression vector is expressed;
(c) recovering one or more monomers from the host cells; and
(d) linking said monomers to produce the oligomer; wherein the oligomer exhibits enhanced stability compared to soluble FLT-1 (sFLT01).
8. The method of claim 7 , wherein said monomers are linked using copper oxidation to form an oligomer.
9. The method of claim 7 , wherein said monomers are linked to each other through a non-protein polymer.
10. The method of claim 9 , wherein said monomers are linked to each other through a multifunctional PEG.
11. The method of claim 7 , wherein the oligomer is a dimer.
12. The method of claim 7 , wherein the oligomer is a trimer.
13. The method of claim 7 , wherein the oligomer is a tetramer.